Franco-Nevada Corporation vs Teladoc Health Inc — how do they compare? Franco-Nevada Corporation trades at $238.3 (market cap $45.36B), while Teladoc Health Inc trades at $5.81 (market cap $1.06B). The key difference: Franco-Nevada Corporation is far larger — about 42.8× Teladoc Health Inc's market cap, and Franco-Nevada Corporation pays a 0.75% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and Teladoc Health Inc for 39 Days on average.
| FNV | TDOC | |
|---|---|---|
Market Cap | $45.36B | $1.06B |
Volume | 787,841 | 3,512,667 |
Sector | Basic Materials | Health |
52-Week High | $280.82 | $9.72 |
52-Week Low | $183.97 | $4.47 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $44.34B | $1.32B |
Dividend Yield | 0.75% | — |
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
TDOC trades at $6.00, up 1.35% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong gross margins of 68.97% but continues to report net losses, with Q3 2026 earnings expected at -$0.22 per share. Recent management changes include the appointment of Michael Grasher as CFO, while the stock faces investor lawsuits and BetterHelp segment challenges.
TDOC presents a high-risk opportunity with significant analyst divergence - 36% recommend buy with $8.83 price target, but persistent losses and negative cash flow in 2025 raise concerns. The integrated care business shows promise, but execution risks and competitive pressures remain key challenges for investors considering this turnaround story.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →